Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

PSNCBAM-1

Negative allosteric modulator of CB1, a research tool with no human data.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₂H₂₁ClN₄O

CID 11560249

Family
ECS pharmacological toolAllosteric modulator
Molar mass
392.90 g/mol

Updated on

In plain terms

PSNCBAM-1 is a laboratory molecule with no connection to hemp: it is found in no plant and is not a consumer product. Researchers use it to dampen the signal of the CB1 receptor without acting at the site targeted by cannabinoids themselves, in order to study how this receptor works. No study in humans was found.

Receptors and activity

Target network

CB1Negative allosteric modulatorIC50 = 32 nM · humancalcium mobilisation, CHO cells overexpressing human CB1, against 100 nM CP 55,940 (pIC50 7.5); pIC50 7.0 in [35S]GTPγS binding and 6.4 in the cAMP assay
  • Blocks or inhibits

The lower the cited value, the closer the target sits to PSNCBAM-1: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PSNCBAM-1.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Negative allosteric modulatorIC50 = 32 nM · human58 out of 100

    Nguyen et al., Bioorg Med Chem 2021 (table 3) (new tab) · calcium mobilisation, CHO cells overexpressing human CB1, against 100 nM CP 55,940 (pIC50 7.5); pIC50 7.0 in [35S]GTPγS binding and 6.4 in the cAMP assay

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

PSNCBAM-1 is a negative allosteric modulator of the CB1 receptor: it binds at a site distinct from the orthosteric pocket and lowers the efficacy of agonists instead of occupying their binding site. Horswill and colleagues showed in 2007, in a yeast reporter assay, that it blocks the effects of CP 55,940, WIN 55,212-2, anandamide and 2-AG; the antagonism, confirmed in [35S]GTPγS binding and cAMP assays, is non-competitive on Schild analysis, with no effect on the CB2 receptor. Its profile is paradoxical: it increases the binding of [3H]CP 55,940 while decreasing the signalling that follows, and its action depends on the agonist, being stronger against CP 55,940 than against WIN 55,212-2. At human CB1 the pIC50 is 7.5 in calcium mobilisation, 7.0 in [35S]GTPγS binding and 6.4 in cAMP assay (Nguyen et al. 2021). In cerebellar electrophysiology, it abolished the CP 55,940-induced drop in the frequency of miniature inhibitory currents, with no clear effect on that of WIN 55,212-2 (Wang et al. 2011). In rats it decreased food intake and body weight in an acute model (Horswill et al. 2007); in mice it reduced ethanol self-administration at 30 mg/kg but also that of a palatable food, without changing ethanol-conditioned place preference, which points to a non-specific hypophagic effect (Buechler et al. 2024). No study in humans was found.

Key sources.

History

Source
An entirely synthetic molecule, known only as a laboratory compound. It comes from a small-molecule library screen run in search of a CB1 antagonist with a mechanism different from that of rimonabant (Horswill et al. 2007).

Origin

Research tool

No biological pathway: PSNCBAM-1 is a synthetic compound (a diarylurea), unrelated to the plant cannabinoid pathway from CBGA.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Allosteric modulator

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

PSNCBAM-1 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Horswill JG et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol, 2007 (new tab)PMID 17592509
  2. Wang X et al. Effects of the allosteric antagonist PSNCBAM-1 on CB1 receptor modulation in the cerebellum. Mol Pharmacol, 2011 (new tab)PMID 21189269
  3. Baillie GL et al. CB1 receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol, 2013 (new tab)PMID 23160940
  4. German N et al. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on PSNCBAM-1. J Med Chem, 2014 (new tab)PMID 25162172
  5. Nguyen T et al. Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorg Med Chem, 2021 (new tab)PMID 34015703
  6. Buechler HM et al. The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect. Pharmacol Biochem Behav, 2024 (new tab)PMID 38679080
  7. PubChem, PSNCBAM-1, CID 11560249 (identifiers and properties) (new tab)

Identifiers

Names

IUPAC name
1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-yl-2-pyridinyl)phenyl]urea
Other names
PSNCBAM 1

Identifiers

Formula
C₂₂H₂₁ClN₄O
PubChem CID
11560249(new tab)
InChIKey
HDAYFSFWIPRJSO-UHFFFAOYSA-N
SMILES
O=C(Nc1ccc(Cl)cc1)Nc1cccc(-c2cccc(N3CCCC3)n2)c1

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.